One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
KALA BIO, Inc.
KALA · NCM · Healthcare · Biotechnology
Current price
$0.17
52-week range
$0.12 - $95.50
Market cap
$3.31M
Balance sheet
Healthy
-11.91x Concerning
Net cash $7.23M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -345.3% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 6.2% (peer median: 11.7%).
What this company does
KALA BIO, Inc.
KALA BIO is a company that creates a special computer system using artificial intelligence (AI) to help other drug companies with their research. This system, called Researgency, is designed to speed up how they discover and develop new medicines, which is important because finding new treatments can take a very long time and cost a lot of money. The money KALA makes primarily comes from selling access to this AI platform to biotechnology and pharmaceutical companies.
How the company got here
KALA BIO, Inc., originally founded as Kala Pharmaceuticals in 2009, has evolved significantly in its journey. The company initially focused on developing therapies for eye diseases using a proprietary nanoparticle technology designed to penetrate mucus. A key turning point was the name change to KALA BIO in August 2023, signaling a strategic shift to better reflect its focus on advancing biologics and embracing artificial intelligence (AI) in its operations. This rebranding also coincided with a strategic initiative to develop an on-premises AI infrastructure platform for the biotechnology industry, leveraging its existing clinical data and research.
What it actually does
KALA BIO is a biopharmaceutical company that is developing innovative treatments for rare and severe eye diseases. They are also building an AI platform to help other biotechnology companies analyze their research data. Think of them as having two main focuses: one is creating new medicines for eye conditions, and the other is providing a specialized technology service for the biotech industry.
Biologics Pipeline (Eye Diseases)
This is KALA BIO's core business of developing new medicines. Their main focus is on creating therapies for serious and rare eye conditions. They use a proprietary technology called the mesenchymal stem cell secretome (MSC-S) platform, which involves using beneficial molecules derived from human stem cells. Their most advanced product candidate, KPI-012, is currently in clinical trials for a condition called persistent corneal epithelial defects (PCED), which is a problem with the eye's healing process. They are also exploring treatments for other eye diseases like Limbal Stem Cell Deficiency and inherited retinal degenerative diseases.
Researgency.ai (AI Infrastructure Platform)
This is KALA BIO's newer venture, focused on providing an artificial intelligence (AI) platform for other biotechnology and pharmaceutical companies. The platform, called Researgency.ai, is designed to be installed directly on a company's own computer systems (on-premises), meaning sensitive research data stays within the company's control. This service helps these companies analyze their vast amounts of research and clinical trial data more effectively, aiming to speed up scientific discovery and decision-making. KALA BIO is using its own data as a test case before offering it more broadly.
What management is betting on now
KALA BIO's management is pursuing a dual strategy: advancing its pipeline of innovative eye disease treatments and growing its AI platform business. They are focused on leveraging their existing clinical trial data and scientific expertise to develop both novel therapies and the Researgency.ai platform. The company aims to become a key AI infrastructure partner for the biotechnology industry, offering a secure, on-premises solution for data analysis. This approach is designed to create recurring revenue streams while continuing to push forward with their drug development efforts.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-1.58M
Diluted EPS
-21.32
Operating cash flow
$-1.53M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.62M
Diluted EPS
-0.14
Operating cash flow
$-2.90M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$686.00K
Diluted EPS
0.88
Operating cash flow
$12.00M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-7.56M
Diluted EPS
-1.07
Operating cash flow
$-18.61M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-11.15M
Diluted EPS
-1.71
Operating cash flow
$-16.56M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-8.95M
Diluted EPS
-1.41
Operating cash flow
$-8.82M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-8.18M
Diluted EPS
-0.86
Operating cash flow
$-4.60M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-8.95M
Diluted EPS
-1.93
Operating cash flow
$-4.72M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.17
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.2M - more cash than debt. Interest coverage -11.9x.
Net debt
$-7.23M
Interest coverage
-11.91x
KALA BIO, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
KALA
BASELINE
KALA BIO, Inc.
Total debt $0.00 Interest coverage -11.91x This is the baseline the peer rows are being compared against.
Total debt $0.00 Interest coverage -52.15x Neither company has much profit cushion over interest right now.
Total debt $693.00K Interest coverage -12.74x Neither company has much profit cushion over interest right now.
Total debt $69.83M Interest coverage -9.08x Neither company has much profit cushion over interest right now.
What you should know
The case for and against KALA
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -345.3% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 6.2% (peer median: 11.7%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.03x
P/B
0.37x
P/S
—
EV/EBITDA
0.16x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-345.3%
ROA
-65.4%
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
6.88x
Quick ratio
4.84x
Total debt
$0.00
Total cash
$7.23M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-10.71
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-11.04M
Free CF TTM
$-32.01M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—